Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN81,7381,76-0,65
Msft0,44
Nokia4,444,582-1,35
IBM-0,93
Mercedes-Benz Group AG48,84548,855-1,02
PFE-0,21
26.06.2025 1:38:52
Indexy online
AD Index online
select
AD Index online
 

  • 25.06.2025
Abbott Labs (ABT.S, Swiss Exchange)
Závěr k 25.6.2025 Změna (%) Změna (CHF) Objem obchodů (CHF)
108,00 0,00 0,00 935
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.06.2025
Popis společnosti

Business Summary: Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Abbott Laboratories revenues increased 4% to $10.36B. Net income increased 8% to $1.33B. Revenues reflect Medical Devices segment increase of 10% to $4.9B, Nutritionals Products segment increase of 4% to $2.15B, Established Pharmaceutical Products segment increase of 3% to $1.26B, United States segment increase of 8% to $4.17B, All other Countries segment increase of 1% to $6.19B.



  • Poslední aktualizace: 26.06.2025
Management společnosti
Data nejsou k dispozici